Welcome to CDC Stacks | Cholesterol Screening for Women: Who Is “At-Risk”? - 30385 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Cholesterol Screening for Women: Who Is “At-Risk”?
Filetype[PDF - 245.42 KB]


Details:
  • Pubmed ID:
    23621744
  • Pubmed Central ID:
    PMC4395876
  • Funding:
    GGF9/Intramural CDC HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Background

    High cholesterol often precedes cardiovascular disease (CVD) and guidelines recommend cholesterol screening among at-risk women. Definitions of CVD risk vary and prevalence of dyslipidemia (abnormal total cholesterol, high-density lipoprotein (HDL-C), or non-HDL-C) among at-risk women may vary by age and definition of CVD risk.

    Methods

    This study used 2007–2008 National Health and Nutrition Examination Survey data (n=1,781), a representative sample of the U.S. civilian, non-institutionalized population, to estimate the proportion of women without previous dyslipidemia diagnosis who are U.S. Preventive Services Task Force (USPSTF) at-risk and American Heart Association (AHA) at-risk. We also report dyslipidemia prevalence stratified by age.

    Results

    Over half (55.0%) of younger women (20–44 years) and 74.2% of older women (≥45 years) were USPSTF at-risk, while nearly all younger and older women had at least one AHA risk factor (99.5% and 99.6%, respectively). Dyslipidemia prevalence among younger women was 47.3% (95% confidence interval [CI]: 42.2– 52.5) for USPSTF-at-risk and 39.5% (95% CI: 35.7–43.4) for AHA at-risk. Among older women, it was 65.5% (95% CI: 60.8–69.9) for USPSTF at-risk and 63.3% (95% CI: 59.0–67.4) for AHA at-risk.

    Conclusions

    The AHA risk definition identified 45% more young women and 25% more older women than the USPSTF risk definition; however, both definitions of at-risk identified similar prevalence estimates of dyslipidemia among women. Given a high prevalence of dyslipidemia among younger women, future research is needed to assess whether identification and treatment of young women with dyslipidemia will decrease CVD mortality among them later in life.